Trastuzumab deruxtecan - Wikipedia
WEBTrastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan).
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic …
WEBSep 15, 2024 · Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WEBJul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2-targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Trastuzumab deruxtecan in HER2-positive advanced breast …
WEBSep 13, 2024 · Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced ...
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for …
WEBMar 23, 2022 · Treatment with trastuzumab deruxtecan showed a benefit over trastuzumab emtansine with respect to progression-free survival, as assessed by blinded independent central review.
Trastuzumab deruxtecan (Enhertu) - Breast Cancer Now
WEBLearn about trastuzumab deruxtecan (Enhertu), a targeted breast cancer therapy, including how it works, who might be offered it and possible side effects. Contact our breast care nurses 0808 800 6000
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic …
WEBAmong patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer who had received one or more lines of endocrine-based therapy, treatment with trastuzumab deruxtecan resulted in longer progression-free survival than chemotherapy.
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.